Cumberland Pharmaceuticals posts $0.20 Q2 loss on $170,000 revenue

Cumberland Pharmaceuticals reported a Q2 net loss of $0.20 per share on revenue of $170,000.

The Nashville-based specialty drugmaker released results for the quarter ended June 30, 2026, on Aug. 4. The company did not disclose consensus estimates, prior-year comparisons, or forward guidance in the release.

The $170,000 in revenue reflects the company's portfolio of hospital and acute-care products, including Acetadote, Caldolor, and Kristalose. The per-share loss of $0.20 extends a run of quarterly deficits for the small-cap drugmaker, which trades on the Nasdaq under the ticker CPIX.

The results show the pressure on Cumberland as it works to stabilize revenue across its branded pharmaceutical lines. Investors will watch the next quarterly report for signs of a turnaround, with the company's cash position and pipeline progress likely to shape the stock's direction in coming months.

This article is for informational purposes only and does not constitute investment advice.